Jorge Cortez, "A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation." ASH, San Diego, CA 2011.
News
News
Press Releases
-
10.04.2012
-
08.29.2012
-
06.11.2012